Back to results
US 9,808,439 B2Granted
Use of tangeretin in cancer treatment
AssigneeMacau University of Science and Technology
InventorsWen-zhe Ma, Sen-ling Feng, Xiao-jun Yao, Zhong-wen Yuan, Liang Liu, Ying Xie
Life of this patent
Estimating the term…
Abstract
The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is tangeretin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.
Claims8
A method comprising:
- treating multidrug resistance cancer by administering a pharmaceutically effective amount of a citrus methoxyflavone and a chemotherapeutic drug to a subject in need thereof,
- wherein the citrus methoxyflavone is tangeretin, the multidrug resistance cancer is paclitaxel resistant-ovarian cancer and the chemotherapeutic drug is paclitaxel;
- wherein the paclitaxel and the tangeretin are administered to the subject in a molar ratio of 0.94:0.84 to 0.94:7.53 to treat the paclitaxel-resistant ovarian cancer.
A method comprising:
- enhancing an efficacy of a chemotherapeutic drug in treating multidrug resistance cancer by administering the chemotherapeutic drug to a subject;
- and
- applying a citrus methoxyflavone to the subject,
- wherein the citrus methoxyflavone is tangeretin, the multidrug resistance cancer is paclitaxel resistant-ovarian cancer and the chemotherapeutic drug is paclitaxel;
- wherein the paclitaxel and the tangeretin are administered to the subject in a molar ratio of 0.94:0.84 to 0.94:7.53 to treat the paclitaxel-resistant ovarian cancer.
2 more elements
Dependencies are inferred from the claim text.